Treatment Outcome Prediction Using Multi-Task Learning: Application to Botulinum Toxin in Gait Rehabilitation

Sensors (Basel). 2022 Nov 3;22(21):8452. doi: 10.3390/s22218452.

Abstract

We propose a framework for optimizing personalized treatment outcomes for patients with neurological diseases. A typical consequence of such diseases is gait disorders, partially explained by command and muscle tone problems associated with spasticity. Intramuscular injection of botulinum toxin type A is a common treatment for spasticity. According to the patient's profile, offering the optimal treatment combined with the highest possible benefit-risk ratio is important. For the prediction of knee and ankle kinematics after botulinum toxin type A (BTX-A) treatment, we propose: (1) a regression strategy based on a multi-task architecture composed of LSTM models; (2) to introduce medical treatment data (MTD) for context modeling; and (3) a gating mechanism to model treatment interaction more efficiently. The proposed models were compared with and without metadata describing treatments and with serial models. Multi-task learning (MTL) achieved the lowest root-mean-squared error (RMSE) (5.60°) for traumatic brain injury (TBI) patients on knee trajectories and the lowest RMSE (3.77°) for cerebral palsy (CP) patients on ankle trajectories, with only a difference of 5.60° between actual and predicted. Overall, the best RMSE ranged from 5.24° to 6.24° for the MTL models. To the best of our knowledge, this is the first time that MTL has been used for post-treatment gait trajectory prediction. The MTL models outperformed the serial models, particularly when introducing treatment metadata. The gating mechanism is efficient in modeling treatment interaction and improving trajectory prediction.

Keywords: botulinum toxin; clinical gait analysis; deep learning; gait rehabilitation; long short-term memory; multi-task learning.

MeSH terms

  • Botulinum Toxins, Type A* / therapeutic use
  • Cerebral Palsy* / rehabilitation
  • Gait
  • Humans
  • Muscle Spasticity
  • Neuromuscular Agents* / therapeutic use
  • Treatment Outcome

Substances

  • Botulinum Toxins, Type A
  • Neuromuscular Agents